Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly

Dong Li, Tara L. Wenger, Christoph Seiler, Michael E. March, Alvaro Gutierrez-Uzquiza, Charlly Kao, Elizabeth Bhoj, Lifeng Tian, Misha Rosenbach, Yichuan Liu, Nora Robinson, Mechenzie Behr, Rosetta Chiavacci, Cuiping Hou, Tiancheng Wang, Marina Bakay, Renata Pellegrino Da Silva, Jonathan A. Perkins, Patrick Sleiman, Michael A. LevinePatricia J. Hicks, Maxim Itki, Yoav Dori, Hakon Hakonarson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Central conducting lymphatic anomaly (CCLA) is one of the complex lymphatic anomalies characterized by dilated lymphatic channels, lymphatic channel dysmotility and distal obstruction affecting lymphatic drainage. We performed whole exome sequencing (WES) of DNA from a four-generation pedigree and examined the consequences of the variant by transfection of mammalian cells and morpholino and rescue studies in zebrafish. WES revealed a heterozygous mutation in EPHB4 (RefSeq NM-004444.4; c.2334+1G>C) and RNA-Seq demonstrated that the EPHB4 mutation destroys the normal donor site, which leads to the use of a cryptic splice donor that results in retention of the intervening 12-bp intron sequence. Transient coexpression of the wild-type and mutant EPHB4 proteins showed reduced phosphorylation of tyrosine, consistent with a lossof- function effect. Zebrafish ephb4a morpholino resulted in vessel misbranching and deformities in the lymphatic vessel development, indicative of possible differentiation defects in lymphatic vessels, mimicking the lymphatic presentations of the patients. Immunoblot analysis using zebrafish lysates demonstrated over-activation of mTORC1 as a consequence of reduced EPHB4 signaling. Strikingly, drugs that inhibit mTOR signaling or RAS-MAPK signaling effectively rescued the misbranching phenotype in a comparable manner. Moreover, knock-in of EPHB4 mutation in HEK293T cells also induced mTORC1 activity. Our data demonstrate the pathogenicity of the identified EPHB4 mutation as a novel cause of CCLA and suggesting that ERK inhibitors may have therapeutic benefits in such patients with complex lymphatic anomalies.

Original languageEnglish (US)
Pages (from-to)3233-3245
Number of pages13
JournalHuman molecular genetics
Volume27
Issue number18
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Zebrafish
Exome
Morpholinos
Mutation
Lymphatic Vessels
EphB4 Receptor
Tissue Donors
Mutant Proteins
Pedigree
DNA Sequence Analysis
Introns
Transfection
Virulence
Tyrosine
Drainage
Phosphorylation
RNA
Phenotype
Pharmaceutical Preparations
mechanistic target of rapamycin complex 1

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Li, D., Wenger, T. L., Seiler, C., March, M. E., Gutierrez-Uzquiza, A., Kao, C., ... Hakonarson, H. (2018). Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly. Human molecular genetics, 27(18), 3233-3245. https://doi.org/10.1093/hmg/ddy218

Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly. / Li, Dong; Wenger, Tara L.; Seiler, Christoph; March, Michael E.; Gutierrez-Uzquiza, Alvaro; Kao, Charlly; Bhoj, Elizabeth; Tian, Lifeng; Rosenbach, Misha; Liu, Yichuan; Robinson, Nora; Behr, Mechenzie; Chiavacci, Rosetta; Hou, Cuiping; Wang, Tiancheng; Bakay, Marina; Da Silva, Renata Pellegrino; Perkins, Jonathan A.; Sleiman, Patrick; Levine, Michael A.; Hicks, Patricia J.; Itki, Maxim; Dori, Yoav; Hakonarson, Hakon.

In: Human molecular genetics, Vol. 27, No. 18, 01.01.2018, p. 3233-3245.

Research output: Contribution to journalArticle

Li, D, Wenger, TL, Seiler, C, March, ME, Gutierrez-Uzquiza, A, Kao, C, Bhoj, E, Tian, L, Rosenbach, M, Liu, Y, Robinson, N, Behr, M, Chiavacci, R, Hou, C, Wang, T, Bakay, M, Da Silva, RP, Perkins, JA, Sleiman, P, Levine, MA, Hicks, PJ, Itki, M, Dori, Y & Hakonarson, H 2018, 'Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly', Human molecular genetics, vol. 27, no. 18, pp. 3233-3245. https://doi.org/10.1093/hmg/ddy218
Li D, Wenger TL, Seiler C, March ME, Gutierrez-Uzquiza A, Kao C et al. Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly. Human molecular genetics. 2018 Jan 1;27(18):3233-3245. https://doi.org/10.1093/hmg/ddy218
Li, Dong ; Wenger, Tara L. ; Seiler, Christoph ; March, Michael E. ; Gutierrez-Uzquiza, Alvaro ; Kao, Charlly ; Bhoj, Elizabeth ; Tian, Lifeng ; Rosenbach, Misha ; Liu, Yichuan ; Robinson, Nora ; Behr, Mechenzie ; Chiavacci, Rosetta ; Hou, Cuiping ; Wang, Tiancheng ; Bakay, Marina ; Da Silva, Renata Pellegrino ; Perkins, Jonathan A. ; Sleiman, Patrick ; Levine, Michael A. ; Hicks, Patricia J. ; Itki, Maxim ; Dori, Yoav ; Hakonarson, Hakon. / Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly. In: Human molecular genetics. 2018 ; Vol. 27, No. 18. pp. 3233-3245.
@article{731e35582f7540878f6795b64f8aa95a,
title = "Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly",
abstract = "Central conducting lymphatic anomaly (CCLA) is one of the complex lymphatic anomalies characterized by dilated lymphatic channels, lymphatic channel dysmotility and distal obstruction affecting lymphatic drainage. We performed whole exome sequencing (WES) of DNA from a four-generation pedigree and examined the consequences of the variant by transfection of mammalian cells and morpholino and rescue studies in zebrafish. WES revealed a heterozygous mutation in EPHB4 (RefSeq NM-004444.4; c.2334+1G>C) and RNA-Seq demonstrated that the EPHB4 mutation destroys the normal donor site, which leads to the use of a cryptic splice donor that results in retention of the intervening 12-bp intron sequence. Transient coexpression of the wild-type and mutant EPHB4 proteins showed reduced phosphorylation of tyrosine, consistent with a lossof- function effect. Zebrafish ephb4a morpholino resulted in vessel misbranching and deformities in the lymphatic vessel development, indicative of possible differentiation defects in lymphatic vessels, mimicking the lymphatic presentations of the patients. Immunoblot analysis using zebrafish lysates demonstrated over-activation of mTORC1 as a consequence of reduced EPHB4 signaling. Strikingly, drugs that inhibit mTOR signaling or RAS-MAPK signaling effectively rescued the misbranching phenotype in a comparable manner. Moreover, knock-in of EPHB4 mutation in HEK293T cells also induced mTORC1 activity. Our data demonstrate the pathogenicity of the identified EPHB4 mutation as a novel cause of CCLA and suggesting that ERK inhibitors may have therapeutic benefits in such patients with complex lymphatic anomalies.",
author = "Dong Li and Wenger, {Tara L.} and Christoph Seiler and March, {Michael E.} and Alvaro Gutierrez-Uzquiza and Charlly Kao and Elizabeth Bhoj and Lifeng Tian and Misha Rosenbach and Yichuan Liu and Nora Robinson and Mechenzie Behr and Rosetta Chiavacci and Cuiping Hou and Tiancheng Wang and Marina Bakay and {Da Silva}, {Renata Pellegrino} and Perkins, {Jonathan A.} and Patrick Sleiman and Levine, {Michael A.} and Hicks, {Patricia J.} and Maxim Itki and Yoav Dori and Hakon Hakonarson",
year = "2018",
month = "1",
day = "1",
doi = "10.1093/hmg/ddy218",
language = "English (US)",
volume = "27",
pages = "3233--3245",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly

AU - Li, Dong

AU - Wenger, Tara L.

AU - Seiler, Christoph

AU - March, Michael E.

AU - Gutierrez-Uzquiza, Alvaro

AU - Kao, Charlly

AU - Bhoj, Elizabeth

AU - Tian, Lifeng

AU - Rosenbach, Misha

AU - Liu, Yichuan

AU - Robinson, Nora

AU - Behr, Mechenzie

AU - Chiavacci, Rosetta

AU - Hou, Cuiping

AU - Wang, Tiancheng

AU - Bakay, Marina

AU - Da Silva, Renata Pellegrino

AU - Perkins, Jonathan A.

AU - Sleiman, Patrick

AU - Levine, Michael A.

AU - Hicks, Patricia J.

AU - Itki, Maxim

AU - Dori, Yoav

AU - Hakonarson, Hakon

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Central conducting lymphatic anomaly (CCLA) is one of the complex lymphatic anomalies characterized by dilated lymphatic channels, lymphatic channel dysmotility and distal obstruction affecting lymphatic drainage. We performed whole exome sequencing (WES) of DNA from a four-generation pedigree and examined the consequences of the variant by transfection of mammalian cells and morpholino and rescue studies in zebrafish. WES revealed a heterozygous mutation in EPHB4 (RefSeq NM-004444.4; c.2334+1G>C) and RNA-Seq demonstrated that the EPHB4 mutation destroys the normal donor site, which leads to the use of a cryptic splice donor that results in retention of the intervening 12-bp intron sequence. Transient coexpression of the wild-type and mutant EPHB4 proteins showed reduced phosphorylation of tyrosine, consistent with a lossof- function effect. Zebrafish ephb4a morpholino resulted in vessel misbranching and deformities in the lymphatic vessel development, indicative of possible differentiation defects in lymphatic vessels, mimicking the lymphatic presentations of the patients. Immunoblot analysis using zebrafish lysates demonstrated over-activation of mTORC1 as a consequence of reduced EPHB4 signaling. Strikingly, drugs that inhibit mTOR signaling or RAS-MAPK signaling effectively rescued the misbranching phenotype in a comparable manner. Moreover, knock-in of EPHB4 mutation in HEK293T cells also induced mTORC1 activity. Our data demonstrate the pathogenicity of the identified EPHB4 mutation as a novel cause of CCLA and suggesting that ERK inhibitors may have therapeutic benefits in such patients with complex lymphatic anomalies.

AB - Central conducting lymphatic anomaly (CCLA) is one of the complex lymphatic anomalies characterized by dilated lymphatic channels, lymphatic channel dysmotility and distal obstruction affecting lymphatic drainage. We performed whole exome sequencing (WES) of DNA from a four-generation pedigree and examined the consequences of the variant by transfection of mammalian cells and morpholino and rescue studies in zebrafish. WES revealed a heterozygous mutation in EPHB4 (RefSeq NM-004444.4; c.2334+1G>C) and RNA-Seq demonstrated that the EPHB4 mutation destroys the normal donor site, which leads to the use of a cryptic splice donor that results in retention of the intervening 12-bp intron sequence. Transient coexpression of the wild-type and mutant EPHB4 proteins showed reduced phosphorylation of tyrosine, consistent with a lossof- function effect. Zebrafish ephb4a morpholino resulted in vessel misbranching and deformities in the lymphatic vessel development, indicative of possible differentiation defects in lymphatic vessels, mimicking the lymphatic presentations of the patients. Immunoblot analysis using zebrafish lysates demonstrated over-activation of mTORC1 as a consequence of reduced EPHB4 signaling. Strikingly, drugs that inhibit mTOR signaling or RAS-MAPK signaling effectively rescued the misbranching phenotype in a comparable manner. Moreover, knock-in of EPHB4 mutation in HEK293T cells also induced mTORC1 activity. Our data demonstrate the pathogenicity of the identified EPHB4 mutation as a novel cause of CCLA and suggesting that ERK inhibitors may have therapeutic benefits in such patients with complex lymphatic anomalies.

UR - http://www.scopus.com/inward/record.url?scp=85055046416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055046416&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddy218

DO - 10.1093/hmg/ddy218

M3 - Article

C2 - 29905864

AN - SCOPUS:85055046416

VL - 27

SP - 3233

EP - 3245

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 18

ER -